GC
BIO icon

Globeflex Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Globeflex Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-236
Closed -$133K – 485
2022
Q1 		$133K Hold
236
– – 0.03% 369
2021
Q4 		$178K Buy
+236
New +$177K 0.04% 365
2013
Q4 		– Sell
-18
Closed -$2K – 622
2013
Q3 		$2K Sell
18
-4,400
-100% -$519K ﹤0.01% 424
2013
Q2 		$495K Buy
+4,418
New +$518K 0.07% 287

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Globeflex Capital's BIO Position: Q2 2022 in Review

Globeflex Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 236 shares — an estimated $133K sold.

Globeflex Capital first reported a position in BIO in Q2 2013 and held it in 4 quarters. The position peaked at $495K in Q2 2013. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

  • Globeflex Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
  • Globeflex Capital sold 236 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $133K.
  • Globeflex Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 4 quarters.
  • Globeflex Capital's Bio-Rad Laboratories Class A position peaked at $495K in Q2 2013.
  • 500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Globeflex Capital's 13F filing for Q2 2022, filed 15 Aug 2022.